Joseph A Lewnard1,2,3, Noga Givon-Lavi4,5, Ron Dagan5. 1. Division of Epidemiology, School of Public Health, University of California, Berkeley, Berkeley, California, USA. 2. Division of Infectious Diseases and Vaccinology, School of Public Health, University of California, Berkeley, Berkeley, California, USA. 3. Center for Computational Biology, College of Engineering, University of California, Berkeley, Berkeley, California, USA. 4. Pediatric Infectious Diseases Unit, Soroka University Medical Center, Beer Sheva, Israel. 5. Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Abstract
INTRODUCTION: Streptococcus pneumoniae is a leading cause of pneumonia among children. However, owing to diagnostic limitations, the protection conferred by pneumococcal conjugate vaccines (PCVs) against pediatric pneumonia attributable to vaccine-serotype pneumococci remains unknown. METHODS: We analyzed data on vaccination and nasopharyngeal pneumococcal detection among children <5 years old with community-acquired alveolar pneumonia (CAAP; "cases") and those without respiratory symptoms ("controls"), who were enrolled in population-based prospective surveillance studies in southern Israel between 2009 and 2018. We measured PCV-conferred protection against carriage of vaccine-serotype pneumococci via the relative risk of detecting these serotypes among vaccinated versus unvaccinated controls. We measured protection against progression of vaccine serotypes from carriage to CAAP via the relative association of vaccine-serotype detection in the nasopharynx with CAAP case status, among vaccinated and unvaccinated children. We measured PCV-conferred protection against CAAP attributable to vaccine-serotype pneumococci via the joint reduction in risks of carriage and disease progression. RESULTS: Our analyses included 1032 CAAP cases and 7743 controls. At ages 12-35 months, a PCV13 schedule containing 2 primary doses and 1 booster dose provided 87.2% (95% confidence interval: 8.1-100.0%) protection against CAAP attributable to PCV13-serotype pneumococci, and 92.3% (-0.9%, 100.0%) protection against CAAP attributable to PCV7-serotype pneumococci. Protection against PCV13-serotype and PCV7-serotype CAAP was 67.0% (-424.3%, 100.0%) and 67.7% (-1962.9%, 100.0%), respectively, at ages 36-59 months. At ages 4-11 months, 2 PCV13 doses provided 98.9% (-309.8%, 100.0%) and 91.4% (-191.4%, 100.0%) against PCV13-serotype and PCV7-serotype CAAP. CONCLUSIONS: Among children, PCV-conferred protection against CAAP attributable to vaccine-targeted pneumococcal serotypes resembles protection against vaccine-serotype invasive pneumococcal disease.
INTRODUCTION: Streptococcus pneumoniae is a leading cause of pneumonia among children. However, owing to diagnostic limitations, the protection conferred by pneumococcal conjugate vaccines (PCVs) against pediatric pneumonia attributable to vaccine-serotype pneumococci remains unknown. METHODS: We analyzed data on vaccination and nasopharyngeal pneumococcal detection among children <5 years old with community-acquired alveolar pneumonia (CAAP; "cases") and those without respiratory symptoms ("controls"), who were enrolled in population-based prospective surveillance studies in southern Israel between 2009 and 2018. We measured PCV-conferred protection against carriage of vaccine-serotype pneumococci via the relative risk of detecting these serotypes among vaccinated versus unvaccinated controls. We measured protection against progression of vaccine serotypes from carriage to CAAP via the relative association of vaccine-serotype detection in the nasopharynx with CAAP case status, among vaccinated and unvaccinated children. We measured PCV-conferred protection against CAAP attributable to vaccine-serotype pneumococci via the joint reduction in risks of carriage and disease progression. RESULTS: Our analyses included 1032 CAAP cases and 7743 controls. At ages 12-35 months, a PCV13 schedule containing 2 primary doses and 1 booster dose provided 87.2% (95% confidence interval: 8.1-100.0%) protection against CAAP attributable to PCV13-serotype pneumococci, and 92.3% (-0.9%, 100.0%) protection against CAAP attributable to PCV7-serotype pneumococci. Protection against PCV13-serotype and PCV7-serotype CAAP was 67.0% (-424.3%, 100.0%) and 67.7% (-1962.9%, 100.0%), respectively, at ages 36-59 months. At ages 4-11 months, 2 PCV13 doses provided 98.9% (-309.8%, 100.0%) and 91.4% (-191.4%, 100.0%) against PCV13-serotype and PCV7-serotype CAAP. CONCLUSIONS: Among children, PCV-conferred protection against CAAP attributable to vaccine-targeted pneumococcal serotypes resembles protection against vaccine-serotype invasive pneumococcal disease.
Authors: John Hansen; Steven Black; Henry Shinefield; Thomas Cherian; Jane Benson; Bruce Fireman; Edwin Lewis; Paula Ray; Janelle Lee Journal: Pediatr Infect Dis J Date: 2006-09 Impact factor: 2.129
Authors: Seema Jain; Derek J Williams; Sandra R Arnold; Krow Ampofo; Anna M Bramley; Carrie Reed; Chris Stockmann; Evan J Anderson; Carlos G Grijalva; Wesley H Self; Yuwei Zhu; Anami Patel; Weston Hymas; James D Chappell; Robert A Kaufman; J Herman Kan; David Dansie; Noel Lenny; David R Hillyard; Lia M Haynes; Min Levine; Stephen Lindstrom; Jonas M Winchell; Jacqueline M Katz; Dean Erdman; Eileen Schneider; Lauri A Hicks; Richard G Wunderink; Kathryn M Edwards; Andrew T Pavia; Jonathan A McCullers; Lyn Finelli Journal: N Engl J Med Date: 2015-02-26 Impact factor: 91.245
Authors: Micah Silaba; Michael Ooko; Christian Bottomley; Joyce Sande; Rachel Benamore; Kate Park; James Ignas; Kathryn Maitland; Neema Mturi; Anne Makumi; Mark Otiende; Stanley Kagwanja; Sylvester Safari; Victor Ochola; Tahreni Bwanaali; Evasius Bauni; Fergus Gleeson; Maria Deloria Knoll; Ifedayo Adetifa; Kevin Marsh; Thomas N Williams; Tatu Kamau; Shahnaaz Sharif; Orin S Levine; Laura L Hammitt; J Anthony G Scott Journal: Lancet Glob Health Date: 2019-03 Impact factor: 38.927
Authors: Elizabeth T Rogawski; Jie Liu; James A Platts-Mills; Furqan Kabir; Paphavee Lertsethtakarn; Mery Siguas; Shaila S Khan; Ira Praharaj; Arinao Murei; Rosemary Nshama; Buliga Mujaga; Alexandre Havt; Irene A Maciel; Darwin J Operario; Mami Taniuchi; Jean Gratz; Suzanne E Stroup; James H Roberts; Adil Kalam; Fatima Aziz; Shahida Qureshi; M Ohedul Islam; Pimmada Sakpaisal; Sasikorn Silapong; Pablo P Yori; Revathi Rajendiran; Blossom Benny; Monica McGrath; Jessica C Seidman; Dennis Lang; Michael Gottlieb; Richard L Guerrant; Aldo A M Lima; Jose Paulo Leite; Amidou Samie; Pascal O Bessong; Nicola Page; Ladaporn Bodhidatta; Carl Mason; Sanjaya Shrestha; Ireen Kiwelu; Estomih R Mduma; Najeeha T Iqbal; Zulfiqar A Bhutta; Tahmeed Ahmed; Rashidul Haque; Gagandeep Kang; Margaret N Kosek; Eric R Houpt Journal: Lancet Glob Health Date: 2018-10-01 Impact factor: 26.763
Authors: Brian Wahl; Katherine L O'Brien; Adena Greenbaum; Anwesha Majumder; Li Liu; Yue Chu; Ivana Lukšić; Harish Nair; David A McAllister; Harry Campbell; Igor Rudan; Robert Black; Maria Deloria Knoll Journal: Lancet Glob Health Date: 2018-07 Impact factor: 26.763
Authors: Joseph A Lewnard; Katia J Bruxvoort; Vennis X Hong; Lindsay R Grant; Luis Jódar; Alejandro Cané; Bradford D Gessner; Sara Y Tartof Journal: J Infect Dis Date: 2022-03-22 Impact factor: 7.759